The trial investigates the pharmacokinetics and pharmacodynamics of insulin detemir when co-administered with liraglutide in patients with type 2 diabetes. Given the increasing prevalence of diabetes and the growing market for combination therapies, successful outcomes could enhance Novo Nordisk's portfolio in diabetes management. The trial's completion in 2009 positions it within a competitive landscape where combination therapies are gaining traction. The results may provide insights into optimizing treatment regimens, potentially leading to improved patient outcomes and increased market share. Additionally, the findings could inform future product development strategies and partnerships.